Here’s what’s interesting. One of the most beaten-down names in the entire S&P 500 just posted one of the most dramatic earnings beats of the entire Q2 season — and the market is still figuring out what it means.
UnitedHealth Group reported this morning.
The numbers were not subtle.
Adjusted earnings came in at $6.38 per share. The Street was expecting $4.90. That’s a 30% beat on the bottom line. Earnings from operations hit $8.0 billion, up sharply from $5.2 billion in the same quarter a year ago. Revenue landed at $112.0 billion, essentially in line with expectations — but the operating leverage underneath it was the real story.
Then the guidance raise. Full-year 2026 adjusted earnings outlook moved to $19.50 to $20.00 per share, up from the prior guide of greater than $18.25. Cash flows from operations are now projected at approximately $24.0 billion for the year, with at least $5.0 billion in planned share repurchases.
The metric that really matters here is the medical care ratio — the percentage of premiums paid out in claims. It fell to 86.7% in Q2 2026, compared to 89.4% in Q2 2025. That’s a 270 basis point improvement year over year. When that number falls in managed care, margins recover fast. The cost base is largely fixed. The math is almost mechanical.
Slight tangent, but it matters. UNH’s stock had a historically rough stretch. From a peak near $600 in late 2024, the stock collapsed all the way to the mid-$230s by August 2025, driven by a brutal combination of elevated medical costs, regulatory pressure, and the aftermath of a high-profile security incident at its Change Healthcare subsidiary. The stock was essentially untouchable for most institutional investors. Sentiment was near rock bottom.
Then something shifted.
Bank of America upgraded the stock in early June, citing improving medical cost trends. Bernstein raised its price target shortly after, pointing to better Medicare Advantage prospects. The stock has recovered significantly off its lows. And now, Q2 just confirmed what the early bulls were seeing in the data.
Optum — UNH’s health services arm — generated $65.7 billion in revenue and $4.0 billion in operating earnings this quarter, with margin expansion of 160 basis points year over year. That’s not a blip. The Optum segment is becoming the company’s most durable growth engine, and the margin trajectory there is what longer-term investors are underwriting.
The UnitedHealthcare insurance segment served 48.5 million consumers and reported $86.0 billion in revenues. The operating margin came in at 4.6%. Not spectacular, but improving — and improving in the right direction.
The risks haven’t disappeared.
Massachusetts sued UNH’s insurance unit in late May, alleging fraud in the state’s Medicaid program. Regulatory exposure in government programs has been a persistent overhang for months. Medicaid enrollment changes, Affordable Care Act pricing pressures, and the broader question of whether medical cost normalization is durable or temporary — these are all still live debates.
The skeptic’s case: one good quarter does not a full recovery make. Other managed care peers are still dealing with elevated cost ratios. If UNH’s outperformance is idiosyncratic and not a sector signal, the valuation premium bakes in expectations the company may struggle to meet.
But here’s the thing. The combination of disciplined medical cost management, a raised full-year guide, $24 billion in projected operating cash flow, and an Optum segment showing real margin expansion is not a setup that usually precedes another leg lower. The quality of this earnings report was high, and the read-through for the sector is broadly positive.
The managed care trade spent most of 2025 being the most avoided corner of healthcare. Today’s number suggests the inflection that analysts had been modeling — but few believed in — may actually be underway. Worth watching closely as the other managed care names report in the coming weeks.
